sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase…
PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development…
SIOUX FALLS, SD / ACCESS Newswire / December 2, 2025 / Avel eCare is pleased to announce the appointment of…
FUKUOKA, Japan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company"), a Japanese labor consulting…
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval PathwayPRINCETON, N.J., Dec. 02, 2025 (GLOBE…
"Inside the explosive rise of a wellness company outpacing a $200B+ global market"Watch the full Morning Show interview → SCOTTSDALE,…
FDA has determined that NRx’s Abbreviated New Drug Application (ANDA) is “substantially complete” and received for review. Assigned GDUFA goal…
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an…
MELBOURNE, Australia and PALM BEACH, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CYIOS Corp. (OTC: CYIO), a diversified holding company…
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing…